(DECIDE) - NCT01064401Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Please note, some trial-specific information on this page is sourced from clinicaltrials.gov.
About
Trial summary
TYPEINTERVENTIONAL
PHASE
Phase
Clinical trials are done in different phases (0-4). Each phase provides important information about the drug. If a drug does not pass a particular phase, it cannot progress to the next phase. Visit the About Clinical Trials page to learn more.
PHASE3
CONDITION
Relapsing-Remitting Multiple Sclerosis
INTERVENTIONS
Interventions
The drug, device, or procedure being tested.
BIOLOGICAL:BIIB019 (Daclizumab High Yield Process)
Daclizumab High Yield Process for subcutaneous injection
DRUG:Interferon beta-1a Placebo
Placebo to interferon beta-1a intramuscular injection
BIOLOGICAL:Interferon beta-1a
Interferon beta-1a for intramuscular injection
DRUG:Daclizumab High Yield Process Placebo
Placebo to Daclizumab High Yield Process subcutaneous injection
ENROLLMENT
Enrollment
The number of participants needed to take part in this trial.
1841 participants
(ACTUAL)
18 Years to 55 Years
(ADULT)
LOCATIONS228
Key dates
Key dates
When the trial is conducted - from the date the first participant is enrolled to the date of the last participants's final visit.
Results from this trial have been made available. Some information may be redacted (edited) to protect privacy, publication rights, and confidential commercial information. To review the information please visit biogentrialtransparency.com.
PDF
Clinical trial registers
Clinical trial registers, like clinicaltrials.gov, provide information about registered clinical trials.
Publishing results for completed clinical trials on clinical trial registers help us share information about our clinical research. The results we publish here are written for healthcare professionals.
Please contact a clinical trial site directly to learn more about the trial. If no contact details are available, or for general inquiries, please contact the Biogen Clinical Trial Center.
